Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3): 105924.
PubMed PubMed Central CAS Google Scholar
Soler ZM, Patel ZM, Turner JH, Holbrook EH. A primer on viral‐associated olfactory loss in the era of COVID‐19. International Forum of Allergy & Rhinology: Wiley Online Library; 2020. p. 814–20.
Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020;20(7):773.
PubMed PubMed Central CAS Google Scholar
Mazucanti CH, Egan JM. SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? Immunity Ageing. 2020;17(1):21. https://doi.org/10.1186/s12979-020-00192-y.
Article PubMed PubMed Central CAS Google Scholar
Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol. 2020;73(2):451–3.
PubMed PubMed Central CAS Google Scholar
Hartl L, Haslinger K, Angerer M, Semmler G, Schneeweiss-Gleixner M, Jachs M, et al. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients. Hepatology. 2019;89:56.
Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–82.
Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–38.
Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol. 2012;8(10):661.
Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol. 2021;89:1–15.
Meijnikman AS, Bruin S, Groen AK, Nieuwdorp M, Herrema H. Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD. J Hepatol. 2021;74(3):748–9.
Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, et al. Implication of non-alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis. J Hepatol. 2020;73(2):451–3.
PubMed PubMed Central CAS Google Scholar
Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181(5):1036-45.e9. https://doi.org/10.1016/j.cell.2020.04.026.
Article PubMed PubMed Central CAS Google Scholar
Arendt BM, Comelli EM, Ma DW, Lou W, Teterina A, Kim T, et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology. 2015;61(5):1565–78.
Xie Z, Bailey A, Kuleshov MV, Clarke DJ, Evangelista JE, Jenkins SL, et al. Gene set knowledge discovery with enrichr. Current Protocols. 2021;1(3): e90.
PubMed PubMed Central CAS Google Scholar
Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605–12.
Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27(3):431–2.
Yu D, Lim J, Wang X, Liang F, Xiao G. Enhanced construction of gene regulatory networks using hub gene information. BMC Bioinformatics. 2017;18(1):1–20.
Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(4):1–7.
Li C, Xu J. Feature selection with the Fisher score followed by the Maximal Clique Centrality algorithm can accurately identify the hub genes of hepatocellular carcinoma. Sci Rep. 2019;9(1):1–11.
Arora S, Rana R, Chhabra A, Jaiswal A, Rani V. miRNA–transcription factor interactions: a combinatorial regulation of gene expression. Mol Genet Genomics. 2013;288(3):77–87.
Sandelin A, Alkema W, Engström P, Wasserman WW, Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 2004;32(1):D91–4.
PubMed PubMed Central CAS Google Scholar
Xia J, Benner MJ, Hancock RE. NetworkAnalyst-integrative approaches for protein–protein interaction network analysis and visual exploration. Nucleic Acids Res. 2014;42(W1):W167–74.
PubMed PubMed Central CAS Google Scholar
Zhou G, Soufan O, Ewald J, Hancock RE, Basu N, Xia J. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res. 2019;47(W1):W234–41.
PubMed PubMed Central CAS Google Scholar
Huang H-Y, Lin YCD, Li J, Huang K-Y, Shrestha S, Hong H-C, et al. miRTarBase 2020: updates to the experimentally validated microRNA–target interaction database. Nucleic Acids Res. 2020;48(D1):D148–54.
Yoo M, Shin J, Kim J, Ryall KA, Lee K, Lee S, et al. DSigDB: drug signatures database for gene set analysis. Bioinformatics. 2015;31(18):3069–71.
PubMed PubMed Central CAS Google Scholar
Piñero J, Bravo À, Queralt-Rosinach N, Gutiérrez-Sacristán A, Deu-Pons J, Centeno E, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 2016;67:943.
Singh A, Hussain S, Antony B. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: a comprehensive systematic review and meta-analysis. Diabetes Metab Syndr. 2021;15(3):813–22.
PubMed PubMed Central Google Scholar
Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, et al. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS ONE. 2020;15(10): e0240400.
PubMed PubMed Central CAS Google Scholar
Martinez MA, Franco S. Impact of COVID-19 in Liver Disease Progression. Hepatology Communications. 2021;5(7):1138–50. https://doi.org/10.1002/hep4.1745.
Article PubMed PubMed Central CAS Google Scholar
Hegyi PJ, Váncsa S, Ocskay K, Dembrovszky F, Kiss S, Farkas N, et al. Metabolic associated fatty liver disease is associated with an increased risk of severe COVID-19: a systematic review with meta-analysis. Front Med. 2021;8: 626425.
Bramante CT, Tignanelli CJ, Dutta N, Jones E, Tamaritz L, Clark J, et al. Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19. MedRxiv. 2020;89:4.
Wu Y, Zhang J, Yu S, Li Y, Zhu J, Zhang K, et al. Cell pyroptosis in health and inflammatory diseases. Cell Death Discovery. 2022;8(1):191. https://doi.org/10.1038/s41420-022-00998-3.
Article PubMed PubMed Central CAS Google Scholar
Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–43.
PubMed PubMed Central Google Scholar
Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255–73.
PubMed PubMed Central CAS Google Scholar
Hoffmann C, Gerber PA, Cavelti-Weder C, Licht L, Kotb R, Al Dweik R, et al. Liver, NAFLD and COVID-19. Hormone Metab Res. 2022;54:522.
Vranić L, Radovan A, Poropat G, Mikolašević I, Milić S. Non-alcoholic fatty liver disease and COVID-19–two pandemics hitting at the same time. Medicina. 2021;57(10):1057.
PubMed PubMed Central Google Scholar
Vanderbeke L, Van Mol P, Van Herck Y, De Smet F, Humblet-Baron S, Martinod K, et al. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nat Commun. 2021;12(1):1–15.
Lu Z, He B, Chen Z, Yan M, Wu L. Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway. BMC Immunol. 2020;21(1):1–9.
Mahmud SH, Al-Mustanjid M, Akter F, Rahman MS, Ahmed K, Rahman MH, et al. Bioinformatics and system biology approach to identify the influences of SARS-CoV-2 infections to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease patients. Briefings Bioinform. 2021;22(5):115.
Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M. New approach for understanding genome variations in KEGG. Nucleic Acids Res. 2019;47(D1):D590–5.
Abdin SM, Elgendy SM, Alyammahi SK, Alhamad DW, Omar HA. Tackling the cytokine storm in COVID-19, challenges and hopes. Life Sci. 2020;257: 118054.
PubMed PubMed Central CAS Google Scholar
Robinson PC, Liew DF, Liew JW, Monaco C, Richards D, Shivakumar S, et al. The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19. Med. 2020;1(1):90–102.
Giraldez MD, Carneros D, Garbers C, Rose-John S, Bustos M. New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology. Nat Rev Gastroenterol Hepatol. 2021;18(11):787–803.
Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. J Allergy Clin Immunol. 2020;146(3):518–34.
留言 (0)